JP2006513154A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006513154A5 JP2006513154A5 JP2004544675A JP2004544675A JP2006513154A5 JP 2006513154 A5 JP2006513154 A5 JP 2006513154A5 JP 2004544675 A JP2004544675 A JP 2004544675A JP 2004544675 A JP2004544675 A JP 2004544675A JP 2006513154 A5 JP2006513154 A5 JP 2006513154A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- alkyl
- cycloalkyl
- aryl
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 36
- 125000003118 aryl group Chemical group 0.000 claims description 35
- 150000001875 compounds Chemical class 0.000 claims description 31
- 229910052739 hydrogen Inorganic materials 0.000 claims description 30
- 239000001257 hydrogen Substances 0.000 claims description 30
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 29
- 229920001515 polyalkylene glycol Chemical group 0.000 claims description 20
- 125000003827 glycol group Chemical group 0.000 claims description 17
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 15
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 11
- 229910052760 oxygen Inorganic materials 0.000 claims description 11
- 239000001301 oxygen Substances 0.000 claims description 11
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 7
- 229910052799 carbon Inorganic materials 0.000 claims description 7
- -1 cyano, nitro, amino Chemical group 0.000 claims description 7
- 125000001475 halogen functional group Chemical group 0.000 claims description 7
- 125000005190 thiohydroxy group Chemical group 0.000 claims description 7
- 125000004385 trihaloalkyl group Chemical group 0.000 claims description 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 17
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 15
- 229910052717 sulfur Inorganic materials 0.000 claims 15
- 239000011593 sulfur Substances 0.000 claims 15
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 11
- ZWJINEZUASEZBH-UHFFFAOYSA-N fenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC=C1 ZWJINEZUASEZBH-UHFFFAOYSA-N 0.000 claims 10
- PIGFYZPCRLYGLF-UHFFFAOYSA-N Aluminum nitride Chemical compound [Al]#N PIGFYZPCRLYGLF-UHFFFAOYSA-N 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 9
- 229910052757 nitrogen Inorganic materials 0.000 claims 8
- 229910052698 phosphorus Inorganic materials 0.000 claims 8
- 239000011574 phosphorus Substances 0.000 claims 8
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 8
- 125000001072 heteroaryl group Chemical group 0.000 claims 6
- 238000000034 method Methods 0.000 claims 5
- 150000002829 nitrogen Chemical class 0.000 claims 5
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 4
- 102000003734 Voltage-Gated Potassium Channels Human genes 0.000 claims 4
- 108090000013 Voltage-Gated Potassium Channels Proteins 0.000 claims 4
- 239000004480 active ingredient Substances 0.000 claims 4
- 125000002723 alicyclic group Chemical group 0.000 claims 4
- 125000003342 alkenyl group Chemical group 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 125000000304 alkynyl group Chemical group 0.000 claims 4
- 125000004104 aryloxy group Chemical group 0.000 claims 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 4
- 150000003017 phosphorus Chemical class 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 4
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims 4
- 125000005309 thioalkoxy group Chemical group 0.000 claims 4
- 125000005296 thioaryloxy group Chemical group 0.000 claims 4
- SILNNFMWIMZVEQ-UHFFFAOYSA-N 1,3-dihydrobenzimidazol-2-one Chemical compound C1=CC=C2NC(O)=NC2=C1 SILNNFMWIMZVEQ-UHFFFAOYSA-N 0.000 claims 3
- MYONAGGJKCJOBT-UHFFFAOYSA-N benzimidazol-2-one Chemical class C1=CC=CC2=NC(=O)N=C21 MYONAGGJKCJOBT-UHFFFAOYSA-N 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 210000003618 cortical neuron Anatomy 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 206010003591 Ataxia Diseases 0.000 claims 2
- 208000020925 Bipolar disease Diseases 0.000 claims 2
- 201000004569 Blindness Diseases 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 206010011878 Deafness Diseases 0.000 claims 2
- 208000032382 Ischaemic stroke Diseases 0.000 claims 2
- 108010006746 KCNQ2 Potassium Channel Proteins 0.000 claims 2
- 208000019695 Migraine disease Diseases 0.000 claims 2
- 208000019022 Mood disease Diseases 0.000 claims 2
- 208000008238 Muscle Spasticity Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 230000036506 anxiety Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 206010015037 epilepsy Diseases 0.000 claims 2
- 230000010370 hearing loss Effects 0.000 claims 2
- 231100000888 hearing loss Toxicity 0.000 claims 2
- 208000016354 hearing loss disease Diseases 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 206010027175 memory impairment Diseases 0.000 claims 2
- 206010027599 migraine Diseases 0.000 claims 2
- 208000005264 motor neuron disease Diseases 0.000 claims 2
- 208000004296 neuralgia Diseases 0.000 claims 2
- 208000021722 neuropathic pain Diseases 0.000 claims 2
- 239000005022 packaging material Substances 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 208000018198 spasticity Diseases 0.000 claims 2
- 206010044652 trigeminal neuralgia Diseases 0.000 claims 2
- 108091006146 Channels Proteins 0.000 claims 1
- 108010038888 KCNQ3 Potassium Channel Proteins 0.000 claims 1
- 208000020358 Learning disease Diseases 0.000 claims 1
- 208000026072 Motor neurone disease Diseases 0.000 claims 1
- 102100034354 Potassium voltage-gated channel subfamily KQT member 2 Human genes 0.000 claims 1
- 230000005856 abnormality Effects 0.000 claims 1
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical class NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000003723 learning disability Diseases 0.000 claims 1
- 230000003340 mental effect Effects 0.000 claims 1
- 229920001281 polyalkylene Polymers 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- 230000002194 synthesizing effect Effects 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 description 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical group ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 2
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41952502P | 2002-10-21 | 2002-10-21 | |
| PCT/IL2003/000855 WO2004035037A2 (en) | 2002-10-21 | 2003-10-21 | Derivatives of n-phenylanthranilic acid and 2-benzimidazolon as potassium channel and/or cortical neuron activity modulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006513154A JP2006513154A (ja) | 2006-04-20 |
| JP2006513154A5 true JP2006513154A5 (https=) | 2006-12-07 |
Family
ID=32108098
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004544675A Pending JP2006513154A (ja) | 2002-10-21 | 2003-10-21 | カリウムチャネルおよび／または皮質ニューロン活性モジュレーターとしての、ｎ−フェニルアントラニル酸および２−ベンズイミダゾロンの誘導体 |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP1553932A2 (https=) |
| JP (1) | JP2006513154A (https=) |
| KR (1) | KR20050074493A (https=) |
| AU (1) | AU2003272068A1 (https=) |
| CA (1) | CA2503075A1 (https=) |
| WO (1) | WO2004035037A2 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7632866B2 (en) | 2002-10-21 | 2009-12-15 | Ramot At Tel Aviv University | Derivatives of N-phenylanthranilic acid and 2-benzimidazolone as potassium channel and/or neuron activity modulators |
| US8765815B2 (en) | 2007-09-20 | 2014-07-01 | Ramot At Tel-Aviv University Ltd. | N-phenyl anthranilic acid derivatives and uses thereof |
| GB0723794D0 (en) | 2007-12-05 | 2008-01-16 | Lectus Therapeutics Ltd | Potassium ion channel modulators and uses thereof |
| GB0813403D0 (en) * | 2008-07-22 | 2008-08-27 | Lectus Therapeutics Ltd | Potassium ion channel modulators & uses thereof |
| CA3077659A1 (en) | 2017-10-09 | 2019-04-18 | Ramot At Tel-Aviv University Ltd. | Modulators of potassium ion and trpv1 channels and uses thereof |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5032189A (https=) * | 1973-07-20 | 1975-03-28 | ||
| JPS5095285A (https=) * | 1973-12-26 | 1975-07-29 | ||
| JPH05132431A (ja) * | 1990-03-28 | 1993-05-28 | Nippon Oil & Fats Co Ltd | 高分子化薬剤およびその製造法 |
| US5565483A (en) * | 1995-06-07 | 1996-10-15 | Bristol-Myers Squibb Company | 3-substituted oxindole derivatives as potassium channel modulators |
| ITMI962356A1 (it) * | 1996-11-13 | 1998-05-13 | Uni Degli Studi Di Brescia D I | Uso di composti derivati da molecole ad attivita' antinfiammatoria di tipo non steroideo per la prevenzione e il trattamento di |
| CA2290509A1 (en) * | 1997-07-01 | 1999-01-14 | Warner-Lambert Company | 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as mek inhibitors |
| US6291442B1 (en) * | 1998-02-03 | 2001-09-18 | The General Hospital Corporation | Pharmacological modulators of voltage-gated potassium ion channels |
| EP1144387A1 (en) * | 1998-12-04 | 2001-10-17 | Neurosearch A/S | New benzimidazolone-, benzoxazolone-, or benzothiazolone derivatives as ion channel modulating agents |
| US6472165B1 (en) * | 1999-08-03 | 2002-10-29 | Arzneimittelwerk Dresden Gmbh | Modulatory binding site in potassium channels for screening and finding new active ingredients |
| US6713454B1 (en) * | 1999-09-13 | 2004-03-30 | Nobex Corporation | Prodrugs of etoposide and etoposide analogs |
| US6413507B1 (en) * | 1999-12-23 | 2002-07-02 | Shearwater Corporation | Hydrolytically degradable carbamate derivatives of poly (ethylene glycol) |
| AU5702201A (en) * | 2000-04-13 | 2001-10-30 | Mayo Foundation | Abeta<sub>42</sub> lowering agents |
| US6429223B1 (en) * | 2000-06-23 | 2002-08-06 | Medinox, Inc. | Modified forms of pharmacologically active agents and uses therefor |
| TWI287984B (en) * | 2000-10-17 | 2007-10-11 | Wyeth Corp | Pharmaceutical composition for modulating bladder function |
| GB0026838D0 (en) * | 2000-11-02 | 2000-12-20 | Glaxo Group Ltd | Treatment method |
| US6593349B2 (en) * | 2001-03-19 | 2003-07-15 | Icagen, Inc. | Bisarylamines as potassium channel openers |
| US8765815B2 (en) * | 2007-09-20 | 2014-07-01 | Ramot At Tel-Aviv University Ltd. | N-phenyl anthranilic acid derivatives and uses thereof |
-
2003
- 2003-10-21 KR KR1020057006856A patent/KR20050074493A/ko not_active Ceased
- 2003-10-21 JP JP2004544675A patent/JP2006513154A/ja active Pending
- 2003-10-21 WO PCT/IL2003/000855 patent/WO2004035037A2/en not_active Ceased
- 2003-10-21 EP EP03753909A patent/EP1553932A2/en not_active Withdrawn
- 2003-10-21 CA CA002503075A patent/CA2503075A1/en not_active Abandoned
- 2003-10-21 AU AU2003272068A patent/AU2003272068A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1043531C (zh) | 嘧啶衍生物及其制备方法和用途 | |
| WO2005092895A3 (en) | Alpha aryl or heteroaryl methyl beta piperidino propanoic acid compounds as orl1-receptor antagonists | |
| JP2005519932A5 (https=) | ||
| RU2004111979A (ru) | Производные 1н-имидазола, обладающие св1-агонистической, частичной св1-агонистической или св1-антагонистической активностью | |
| RU2004107131A (ru) | Новые производные 4,5-дигидро-1h-пиразола, имеющие cb1- антагонистическую активность | |
| JP2006504710A5 (https=) | ||
| RU2007105350A (ru) | 3-(гетероарилокси)-2-алкил-1-азабициклоалкильные производные, как лиганды альфа-7-nachr (никотиновых ацетилхолиновых рецепторов), предназначенные для лечения заболеваний центральной нервной системы | |
| MA32088B1 (fr) | Dérivés bicycliques de carboxamides azabicycliques, leur préparation et leur application en thérapeutique | |
| ATE478872T1 (de) | Pyrazoloä4,3-düpyrimidine, verfahren zu ihrer herstellung und therapeutische anwendung | |
| JP2006502119A5 (https=) | ||
| RU2006131132A (ru) | 1,3,5,-тризамещенные производные 4,5-дигидро-1н-пиразола, обладающие св1-антагонистической активностью | |
| RU2008101525A (ru) | Производные пиримидина для лечения заболеваний нервной системы, опосредуемых гаммааминомасляной кислотой в (гамк в) | |
| JP2004518723A5 (https=) | ||
| HUP0102851A2 (hu) | Parazitaellenes artemizinin-származékok (endoperoxidok), eljárás előállításukra és a vegyületeket tartalmazó gyógyászati készítmények | |
| AU623733B2 (en) | Benzofused-n-containing heterocyle derivatives | |
| RU2008119692A (ru) | Новые 1-азабициклоалкилпроизводные для лечения психических растройств | |
| KR960700268A (ko) | 티아졸리딘 유도체, 이의 제조 방법 및 이를 함유한 약제(thiazolidine derivatives, prepartion thereof and drugs containing same) | |
| CA2352405A1 (fr) | Nouveaux derives de diphenyluree, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
| CA2336412A1 (en) | Medicament for treatment of diabetes | |
| WO2004054977A1 (en) | Nicotinamide-based kinase inhibitors | |
| JP2005519989A5 (https=) | ||
| CN1188475A (zh) | 胍衍生物,其中间体及其产物的制备方法 | |
| EP2088142A3 (en) | Dihydropyrimidines, process for their preparation and use thereof. | |
| CA2440014A1 (en) | Beta-carboline derivatives and its pharmaceutical use against depression and anxiety | |
| JP2006513154A5 (https=) |